Background The elimination of blinding trachoma focuses on controlling Chlamydia trachomatis infection through mass antibiotic treatment and measures to limit transmission. As the prevalence of disease declines, uncertainty increases over the most effective strategy for treatment. There are little long-term data on the effect of treatment on infection, especially in low prevalence settings, on which to base guidelines. Methodology/Principal Findings The population of a cluster of 14 Gambian villages with endemic trachoma was examined on seven occasions over five years (baseline, 2, 6, 12, 17, 30 and 60 months). Mass antibiotic treatment was given at baseline only. All families had accessible clean water all year round. New latrines were installed in each household after 17 months. Conjunctival swab samples were collected and tested for C. trachomatis by PCR. Before treatment the village-level prevalence of follicular trachoma in 1 to 9 year olds (TF%1–9) was 15.4% and C. trachomatis was 9.7%. Antibiotic treatment coverage was 83% of the population. In 12 villages all baseline infection cleared and few sporadic cases were detected during the following five years. In the other two villages treatment was followed by increased infection at two months, which was associated with extensive contact with other untreated communities. The prevalence of infection subsequently dropped to 0% in these 2 villages and 0.6% for the whole population by the end of the study in the absence of any further antibiotic treatment. However, several villages had a TF%1–9 of >10%, the threshold for initiating or continuing mass antibiotic treatment, in the absence of any detectable C. trachomatis. Conclusions/Significance A single round of mass antibiotic treatment may be sufficient in low prevalence settings to control C. trachomatis infection when combined with environmental conditions, which suppress transmission, such as a good water supply and sanitation.
References
[1]
Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, et al. (2004) Global data on visual impairment in the year 2002. Bull World Health Organ 82: 844–851. doi: /S0042-96862004001100009
[2]
Mariotti SP, Pascolini D, Rose-Nussbaumer J (2009) Trachoma: global magnitude of a preventable cause of blindness. Br J Ophthalmol 93: 563–568. doi: 10.1136/bjo.2008.148494
[3]
(1998) Global Elimination of Blinding Trachoma. Resolution WHA 51.11. Adopted by the World Health Assembly 16 May 1998.
[4]
Dolin PJ, Faal H, Johnson GJ, Ajewole J, Mohamed AA, et al. (1998) Trachoma in The Gambia. Br J Ophthalmol 82: 930–933. doi: 10.1136/bjo.82.8.930
[5]
Wright HR, Taylor HR (2005) Clinical examination and laboratory tests for estimation of trachoma prevalence in a remote setting: what are they really telling us? Lancet Infect Dis 5: 313–320. doi: 10.1016/S1473-3099(05)70116-X
[6]
Burton MJ, Holland MJ, Faal N, Aryee EA, Alexander ND, et al. (2003) Which members of a community need antibiotics to control trachoma? Conjunctival Chlamydia trachomatis infection load in Gambian villages. Invest Ophthalmol Vis Sci 44: 4215–4222. doi: 10.1167/iovs.03-0107
[7]
World Health Organization (1997) Future Approaches to Trachoma Control. Report of a Global Scientific Meeting. Geneva, 17–20 June 1996. Geneva: World Health Organization.
[8]
World Health Organization (2004) Report of the 2nd global scientific meeting on trachoma. Geneva: World Health Organization.
[9]
Burton MJ, Holland MJ, Makalo P, Aryee EA, Alexander ND, et al. (2005) Re-emergence of Chlamydia trachomatis infection after mass antibiotic treatment of a trachoma-endemic Gambian community: a longitudinal study. Lancet 365: 1321–1328. doi: 10.1016/S0140-6736(05)61029-X
[10]
Dawson CR, Jones BR, Tarizzo ML (1981) Guide to Trachoma Control. Geneva: World Health Organization.
[11]
Thylefors B, Dawson CR, Jones BR, West SK, Taylor HR (1987) A simple system for the assessment of trachoma and its complications. Bull World Health Organ 65: 477–483.
[12]
Solomon AW, Holland MJ, Burton MJ, West SK, Alexander ND, et al. (2003) Strategies for control of trachoma: observational study with quantitative PCR. Lancet 362: 198–204. doi: 10.1016/S0140-6736(03)13909-8
[13]
Alexander ND, Solomon AW, Holland MJ, Bailey RL, West SK, et al. (2005) An index of community ocular Chlamydia trachomatis load for control of trachoma. Trans R Soc Trop Med Hyg 99: 175–177. doi: 10.1016/j.trstmh.2004.05.003
[14]
Armitage P, Berry G, Matthews JNS (2001) Methods in Medical Research. Oxford: Blackwell Scientific Publishers.
[15]
Kerry SM, Bland JM (2001) Unequal cluster sizes for trials in English and Welsh general practice: implications for sample size calculations. Stat Med 20: 377–390. doi: 10.1002/1097-0258(20010215)20:3<377::AID-SIM799>3.0.CO;2-N
[16]
Andreasen AA, Burton MJ, Holland MJ, Polley S, Faal N, et al. (2008) Chlamydia trachomatis ompA Variants in Trachoma: What Do They Tell Us? PLoS Negl Trop Dis 2: e306. doi: 10.1371/journal.pntd.0000306
[17]
Chidambaram JD, Alemayehu W, Melese M, Lakew T, Yi E, et al. (2006) Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA 295: 1142–1146. doi: 10.1001/jama.295.10.1142
[18]
Lakew T, House J, Hong KC, Yi E, Alemayehu W, et al. (2009) Reduction and return of infectious trachoma in severely affected communities in ethiopia. PLoS Negl Trop Dis 3: e376. doi: 10.1371/journal.pntd.0000376
[19]
Biebesheimer JB, House J, Hong KC, Lakew T, Alemayehu W, et al. (2009) Complete local elimination of infectious trachoma from severely affected communities after six biannual mass azithromycin distributions. Ophthalmology 116: 2047–2050. doi: 10.1016/j.ophtha.2009.04.041
[20]
Harding-Esch EM, Edwards T, Sillah A, Sarr I, Roberts CH, et al. (2009) Active Trachoma and Ocular Chlamydia trachomatis Infection in Two Gambian Regions: On Course for Elimination by 2020? PLoS Negl Trop Dis 3: e573. doi: 10.1371/journal.pntd.0000573
[21]
Dolin PJ, Faal H, Johnson GJ, Minassian D, Sowa S, et al. (1997) Reduction of trachoma in a sub-Saharan village in absence of a disease control programme. Lancet 349: 1511–1512. doi: 10.1016/S0140-6736(97)01355-X
[22]
Hoechsmann A, Metcalfe N, Kanjaloti S, Godia H, Mtambo O, et al. (2001) Reduction of trachoma in the absence of antibiotic treatment: evidence from a population-based survey in Malawi. Ophthalmic Epidemiol 8: 145–153. doi: 10.1076/opep.8.2.145.4169
[23]
Taylor HR, Velasco FM, Sommer A (1985) The ecology of trachoma: an epidemiological study in southern Mexico. Bull World Health Organ 63: 559–567.
[24]
Taylor HR, West SK, Mmbaga BB, Katala SJ, Turner V, et al. (1989) Hygiene factors and increased risk of trachoma in central Tanzania. Arch Ophthalmol 107: 1821–1825. doi: 10.1001/archopht.1989.01070020903037
[25]
West S, Munoz B, Lynch M, Kayongoya A, Chilangwa Z, et al. (1995) Impact of face-washing on trachoma in Kongwa, Tanzania. Lancet 345: 155–158. doi: 10.1016/S0140-6736(95)90167-1
[26]
Emerson PM, Lindsay SW, Walraven GE, Faal H, Bogh C, et al. (1999) Effect of fly control on trachoma and diarrhoea. Lancet 353: 1401–1403. doi: 10.1016/S0140-6736(98)09158-2
[27]
Emerson PM, Lindsay SW, Alexander N, Bah M, Dibba SM, et al. (2004) Role of flies and provision of latrines in trachoma control: cluster-randomised controlled trial. Lancet 363: 1093–1098. doi: 10.1016/S0140-6736(04)15891-1
[28]
Emerson PM, Bailey RL, Walraven GE, Lindsay SW (2001) Human and other faeces as breeding media of the trachoma vector Musca sorbens. Med Vet Entomol 15: 314–320. doi: 10.1046/j.0269-283x.2001.00318.x
[29]
West SK, Emerson PM, Mkocha H, McHiwa W, Munoz B, et al. (2006) Intensive insecticide spraying for fly control after mass antibiotic treatment for trachoma in a hyperendemic setting: a randomised trial. Lancet 368: 596–600. doi: 10.1016/S0140-6736(06)69203-9
[30]
Chidambaram JD, Bird M, Schiedler V, Fry AM, Porco T, et al. (2004) Trachoma decline and widespread use of antimicrobial drugs. Emerg Infect Dis 10: 1895–1899. doi: 10.3201/eid1011.040476
[31]
Bailey R, Duong T, Carpenter R, Whittle H, Mabey D (1999) The duration of human ocular Chlamydia trachomatis infection is age dependent. Epidemiol Infect 123: 479–486. doi: 10.1017/S0950268899003076
[32]
Grassly NC, Ward ME, Ferris S, Mabey DC, Bailey RL (2008) The natural history of trachoma infection and disease in a gambian cohort with frequent follow-up. PLoS Negl Trop Dis 2: e341. doi: 10.1371/journal.pntd.0000341
[33]
Biebesheimer JB, House J, Hong KC, Lakew T, Alemayehu W, et al. (2009) Complete Local Elimination of Infectious Trachoma from Severely Affected Communities after Six Biannual Mass Azithromycin Distributions. Ophthalmology. doi: 10.1016/j.ophtha.2009.04.041
[34]
Solomon AW, Harding-Esch E, Alexander ND, Aguirre A, Holland MJ, et al. (2008) Two doses of azithromycin to eliminate trachoma in a Tanzanian community. N Engl J Med 358: 1870–1871. doi: 10.1056/NEJMc0706263
[35]
Schachter J, West SK, Mabey D, Dawson CR, Bobo L, et al. (1999) Azithromycin in control of trachoma. Lancet 354: 630–635. doi: 10.1016/S0140-6736(98)12387-5
[36]
Burton MJ, Adegbola RA, Kinteh F, Ikumapayi UN, Foster A, et al. (2007) Bacterial infection and trachoma in the gambia: a case control study. Invest Ophthalmol Vis Sci 48: 4440–4444. doi: 10.1167/iovs.07-0315
[37]
Burton MJ, Bailey RL, Jeffries D, Rajak SN, Adegbola RA, et al. (2010) Conjunctival expression of matrix metalloproteinase and proinflammatory cytokine genes after trichiasis surgery. Invest Ophthalmol Vis Sci 51: 3583–3590. doi: 10.1167/iovs.09-4550
[38]
Burton MJ, Bailey RL, Jeffries D, Mabey DC, Holland MJ (2004) Cytokine and fibrogenic gene expression in the conjunctivas of subjects from a Gambian community where trachoma is endemic. Infect Immun 72: 7352–7356. doi: 10.1128/IAI.72.12.7352-7356.2004
